Boehringer Ingelheim: Clinical Trials & Research Profile
Biopharma Industry (Ingelheim, DE / Ridgefield, CT) · Primary Focus: Endocrinology, Obesity, and Metabolic
| Clinical Trial Metric | Verified Public Record |
|---|---|
| Organization Type | Consolidated Trial Sponsor |
| Institutional Sector & Location | Biopharma Industry (Ingelheim, DE / Ridgefield, CT) |
| Primary Therapeutic Area | Endocrinology, Obesity, and Metabolic |
| Active Phase II & III Studies | 45 active (28 recruiting now) |
| Total Tracked Studies (2018 to 2026) | 139 (94 with California sites) |
| Completed vs Early-Stopped Studies | 70 completed / 24 stopped (17.3% stop rate) |
| Median Closed Enrollment | 156 participants |
| FDA Drugs@FDA Original Approvals | 54 all-time (6 from 2018 to 2026) |
| Physical Hospital Site Disclosure | 99.9% named hospital slots |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.
Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI -> · AI for Healthcare · Healthcare Price & Patent Cliff Crosswalk